Literature DB >> 28558139

Safety and tolerability of surfactant nasal irrigation.

Justin H Turner1, Jeffanie Wu1, Cindy A Dorminy1, Rakesh K Chandra1.   

Abstract

BACKGROUND: Abnormal mucus composition and bacterial biofilms are thought to contribute to the pathophysiology of rhinosinusitis. Addition of a mucoactive surfactant to saline irrigation solution has been hypothesized to address these factors. We evaluated the safety and tolerability of a reformulated surfactant in a sample of normal subjects.
METHODS: A total of 33 volunteers were randomly assigned to receive either surfactant solution or buffered saline at baseline in a controlled crossover study design. Each subject underwent rhinoscopic exam and in-office smell testing via the 40-question smell identification test (SIT). Those with non-normosmic results or active rhinitis symptoms were excluded. Subjects were instructed to irrigate twice daily with the selected solution for 1 week while keeping a daily diary. For week 2, treatment was stopped. During week 3, each group switched to the other treatment. Exam, SIT, and degree of congestion were assessed after each phase.
RESULTS: Use of surfactant led to a marginal reduction in mean SIT score of 1.5 points, which was statistically significant (p = 0.012). A clinically meaningful reduction in SIT score, defined as ≥4 points, was observed in 18% (6/33) of subjects after surfactant vs 3% (1/33) after saline (p = 0.046). During the surfactant phase, moderate or severe congestion was reported in 29% (8/28) of subjects completing the diary. In contrast, only 6% (2/32) of subjects reported moderate congestion after the saline phase (p = 0.021).
CONCLUSION: In normal volunteers, surfactant nasal irrigation may be associated with tolerability issues due to congestion. A subset may experience reduction in olfactory acuity that appears reversible.
© 2017 ARS-AAOA, LLC.

Entities:  

Keywords:  congestion; nasal irrigation; olfaction; sinus irrigation; smell; smell identification testing; surfactant

Mesh:

Substances:

Year:  2017        PMID: 28558139     DOI: 10.1002/alr.21959

Source DB:  PubMed          Journal:  Int Forum Allergy Rhinol        ISSN: 2042-6976            Impact factor:   3.858


  6 in total

1.  Interim analysis of an open-label randomized controlled trial evaluating nasal irrigations in non-hospitalized patients with coronavirus disease 2019.

Authors:  Kyle S Kimura; Michael H Freeman; Bronson C Wessinger; Veerain Gupta; Quanhu Sheng; Li Ching Huang; Kate Von Wahlde; Suman R Das; Naweed I Chowdhury; Justin H Turner
Journal:  Int Forum Allergy Rhinol       Date:  2020-10-20       Impact factor: 3.858

Review 2.  Topical Antibiofilm Agents With Potential Utility in the Treatment of Chronic Rhinosinusitis: A Narrative Review.

Authors:  Samuel J M Hale; Brett Wagner Mackenzie; Christian A Lux; Kristi Biswas; Raymond Kim; Richard G Douglas
Journal:  Front Pharmacol       Date:  2022-06-13       Impact factor: 5.988

Review 3.  Topical Oral and Intranasal Antiviral Agents for Coronavirus Disease 2019 (COVID-19).

Authors:  Victor B Hsue; Kyohei Itamura; Arthur W Wu; Elisa A Illing; Kevin J Sokoloski; Bree A Weaver; Benjamin P Anthony; Nathan Hughes; Jonathan Y Ting; Thomas S Higgins
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

Review 4.  Mucus, mucins, and cystic fibrosis.

Authors:  Cameron Bradley Morrison; Matthew Raymond Markovetz; Camille Ehre
Journal:  Pediatr Pulmonol       Date:  2019-11

Review 5.  Current Perspective on Nasal Delivery Systems for Chronic Rhinosinusitis.

Authors:  Junhu Tai; Kijeong Lee; Tae Hoon Kim
Journal:  Pharmaceutics       Date:  2021-02-10       Impact factor: 6.321

Review 6.  Using the Intranasal Route to Administer Drugs to Treat Neurological and Psychiatric Illnesses: Rationale, Successes, and Future Needs.

Authors:  Andrew Lofts; Fahed Abu-Hijleh; Nicolette Rigg; Ram K Mishra; Todd Hoare
Journal:  CNS Drugs       Date:  2022-06-27       Impact factor: 6.497

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.